dc.contributor.author |
Pavlyukovich, N. |
|
dc.contributor.author |
Pavlyukovich, O. |
|
dc.contributor.author |
Buriak, O.G. |
|
dc.contributor.author |
Chympoy, C. |
|
dc.date.accessioned |
2017-02-20T10:47:40Z |
|
dc.date.available |
2017-02-20T10:47:40Z |
|
dc.date.issued |
2016 |
|
dc.identifier.other |
УДК 616.12-008.46:616.379-008.64]-07-0361-085.225.2 |
|
dc.identifier.uri |
http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/12115 |
|
dc.description.abstract |
Chronic heart failure of ischemic origin complicated by concomitant diabetes mellitus type 2 is characterized by significant decreasing of the quality of life in general, and of physical and psychological welfare, self-service and independence of action, same as personal implementation particularly. Inclusion of telmisartan to the scheme of complex treatment of the patients with chronic heart failure and diabetes mellitus type 2 results in the improvement of the patients’ quality of life as well as its main components |
ru_RU |
dc.language.iso |
en |
ru_RU |
dc.publisher |
“THE UNITY OF SCIENCE” April, 2016 |
ru_RU |
dc.subject |
chronic heart failure |
ru_RU |
dc.subject |
diabetes mellitus type 2 |
ru_RU |
dc.subject |
quality of life |
ru_RU |
dc.subject |
telmisartan |
ru_RU |
dc.title |
CHRONIC HEART FAILURE AND DIABETES MELLITUS TYPE 2: QUALITY OF LIFE AND POSSIBILITY OF ITS CORRECTION |
ru_RU |
dc.type |
Article |
ru_RU |